Search

Your search keyword '"Katharina S. Götze"' showing total 5 results
Start Over Author "Katharina S. Götze" Publisher american association for cancer research (aacr)
5 results on '"Katharina S. Götze"'

1. Supplementary Methods from AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia

Author

Hind Medyouf, Sourav Ghosh, Carla V. Rothlin, Katharina S. Götze, Halvard Bonig, Jacques Ghysdael, Vladimir Benes, Uwe Platzbecker, Tobias Schmid, Andreas Weigert, Marc Schmitz, Omar Abdel-Wahab, Christine Tran Quang, Elisabeth Strack, Eiman Elwakeel, Jörn Meinel, Anne-Sophie Kubasch, Patrick N. Harter, Jenny Roesler, Julia Slotta-Huspenina, Bianka Baying, Jonathan JM. Landry, Michèle C. Buck, Emily Alberto, Petra Dinse, Maresa Weitmann, Anna-Lena Schäfer, Luise Müller, Ioanna Tsoukala, Carolin Wachtel, Ewelina Czlonka, Ivan-Maximilano Kur, Alexander Schäffer, Aleksandra Nevmerzhitskaya, Devona Soetopo, Arnaud Descot, and Irene Tirado-Gonzalez

Abstract

Supplementary Methods

Published
2023
Full Text
View/download PDF

2. Data from AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia

Author

Hind Medyouf, Sourav Ghosh, Carla V. Rothlin, Katharina S. Götze, Halvard Bonig, Jacques Ghysdael, Vladimir Benes, Uwe Platzbecker, Tobias Schmid, Andreas Weigert, Marc Schmitz, Omar Abdel-Wahab, Christine Tran Quang, Elisabeth Strack, Eiman Elwakeel, Jörn Meinel, Anne-Sophie Kubasch, Patrick N. Harter, Jenny Roesler, Julia Slotta-Huspenina, Bianka Baying, Jonathan JM. Landry, Michèle C. Buck, Emily Alberto, Petra Dinse, Maresa Weitmann, Anna-Lena Schäfer, Luise Müller, Ioanna Tsoukala, Carolin Wachtel, Ewelina Czlonka, Ivan-Maximilano Kur, Alexander Schäffer, Aleksandra Nevmerzhitskaya, Devona Soetopo, Arnaud Descot, and Irene Tirado-Gonzalez

Abstract

Acute leukemias are systemic malignancies associated with a dire outcome. Because of low immunogenicity, leukemias display a remarkable ability to evade immune control and are often resistant to checkpoint blockade. Here, we discover that leukemia cells actively establish a suppressive environment to prevent immune attacks by co-opting a signaling axis that skews macrophages toward a tumor-promoting tissue repair phenotype, namely the GAS6/AXL axis. Using aggressive leukemia models, we demonstrate that ablation of the AXL receptor specifically in macrophages, or its ligand GAS6 in the environment, stimulates antileukemic immunity and elicits effective and lasting natural killer cell– and T cell–dependent immune response against naïve and treatment-resistant leukemia. Remarkably, AXL deficiency in macrophages also enables PD-1 checkpoint blockade in PD-1–refractory leukemias. Finally, we provide proof-of-concept that a clinical-grade AXL inhibitor can be used in combination with standard-of-care therapy to cure established leukemia, regardless of AXL expression in malignant cells.Significance:Alternatively primed myeloid cells predict negative outcome in leukemia. By demonstrating that leukemia cells actively evade immune control by engaging AXL receptor tyrosine kinase in macrophages and promoting their alternative priming, we identified a target which blockade, using a clinical-grade inhibitor, is vital to unleashing the therapeutic potential of myeloid-centered immunotherapy.This article is highlighted in the In This Issue feature, p. 2659

Published
2023
Full Text
View/download PDF

3. Supplementary Figures from AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia

Author

Hind Medyouf, Sourav Ghosh, Carla V. Rothlin, Katharina S. Götze, Halvard Bonig, Jacques Ghysdael, Vladimir Benes, Uwe Platzbecker, Tobias Schmid, Andreas Weigert, Marc Schmitz, Omar Abdel-Wahab, Christine Tran Quang, Elisabeth Strack, Eiman Elwakeel, Jörn Meinel, Anne-Sophie Kubasch, Patrick N. Harter, Jenny Roesler, Julia Slotta-Huspenina, Bianka Baying, Jonathan JM. Landry, Michèle C. Buck, Emily Alberto, Petra Dinse, Maresa Weitmann, Anna-Lena Schäfer, Luise Müller, Ioanna Tsoukala, Carolin Wachtel, Ewelina Czlonka, Ivan-Maximilano Kur, Alexander Schäffer, Aleksandra Nevmerzhitskaya, Devona Soetopo, Arnaud Descot, and Irene Tirado-Gonzalez

Abstract

Supplementary Figures and Figure legends

Published
2023
Full Text
View/download PDF

4. Supplementary Figures 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Author

Katharina S. Götze, Robert A.J. Oostendorp, Christian Peschel, Konstanze Döhner, Sabine Kayser, Katarina Lind, Christina Holzwarth, Sally Rushton, Stefanie Marz, and Amanda Parmar

Abstract

Supplementary Figures 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Published
2023
Full Text
View/download PDF

5. Supplementary Tables 1-2, Figures Legends 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Author

Katharina S. Götze, Robert A.J. Oostendorp, Christian Peschel, Konstanze Döhner, Sabine Kayser, Katarina Lind, Christina Holzwarth, Sally Rushton, Stefanie Marz, and Amanda Parmar

Abstract

Supplementary Tables 1-2, Figures Legends 1-4 from Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results